Is Receptor-Interacting Protein Kinase 3 a Viable Therapeutic Target for Mycobacterium tuberculosis Infection?
Michael D Stutz, Samar Ojaimi, Gregor Ebert, Marc Pellegrini
Frontiers in Immunology | FRONTIERS MEDIA SA | Published : 2018
Awarded by National Health and Medical Research Council Australia
This work was supported by National Health and Medical Research Council Australia (Grants 1006592, 1045549, and 1065626 to MP and 1056282 to SO). The Sylvia & Charles Viertel Senior Medical Research Fellowship (MP), the Victorian State Government Operational Infrastructure Support, and the Independent Research Institutes Infrastructure Support Scheme of the Australian Government National Health and Medical Research Council.